Restricted accessResearch articleFirst published online 1990-7
Determination of Plasma Concentrations of Cyclandelate and Mandelic Acid in Patients with Generalized Atherosclerotic Vasculopathy Treated with Oral Cyclandelate
Cyclandelate, a vasoactive substance consisting of the mandelic acid ester of 3,3,5-trimethylcyclohexanol, was administered to 10 patients with cerebrovascular and/or peripheral vascular disease. Blood specimens were collected at 1 − 6 h after oral administration of 1600 mg cyclandelate, and the ester and acid were extracted from plasma in acid medium using n-hexane/isopropyl alcohol. The concentrations were determined by a high-performance liquid chromatography isocratic system. The highest plasma cyclandelate concentrations were detected at the third hour, whereas plasma mandelic acid concentrations were still increasing 6 h after administration.
TimmermanH, WallRJ, BenyonJSE: Cyclospasmol: new insights into basic mechanisms in relation to clinical effects. Br J Clin Pract1984; 38: 1–79.
2.
BallJAC, TaylorAR: Effect of cyclandelate on mental functions and cerebral blood flow in elderly patients. Br Med J1967; iii: 525–528.
3.
RaoDB: Cyclandelate in the treatment of senile mental changes: a double-blind evaluation. J Am Geriatr Soc1977; 25: 548–551.
4.
SouranderL, BlakemoreCB: Effects of Cyclospasmol upon sensory parameters in patients recovering from cerebrovascular accidents. Angiology1978; 29: 133–138.
5.
KuhnRA: Effect of cyclandelate upon cerebral flow in patients with stroke. Angiology1966; 17: 422–430.
6.
Van WijkTD: The treatment of peripheral vascular diseases with Cyclospasmol. Angiology1953; 4: 103–113.
7.
RavinaA: Traitement des troubles de la circulation périphérique par l'ester amygdalique du 3,3,5-trimethyl-cyclohexanol. Presse Med1963; 71: 727–728.
8.
ReichT: Cyclandelate: effect on circulatory measurements and exercise tolerance in chronic arterial insufficiency of the lower limbs. J Am Geriatr Soc1977; 25: 202–205.
9.
ForconiS, CappelliR, PieragalliD: Effect of a single administration of cyclandelate on some theological and peripheral haemodynamic parameters of peripheral arterial disease patients. In: Microcirculation – an Update (TsuchiyaM, AsanoM, MishimaY, eds) Amsterdam: Elsevier, 1987; pp 537–538.
10.
Van den HovenWE, HallDWR: Inhibition of human platelet functions by cyclandelate. Drugs1987; 33 (2): 41–52.
11.
Van den HovenWE, HallDWR, BurnsJW: Cyclandelate and a number of its metabolites inhibit discocyte echinocyte transformations of human erythrocytes. Br J Clin Pract1984; 38: 26–29.
12.
HallDWR, Van den HovenWE: Influence of cyclandelate on in vitro red blood cell deforma-bility. Drugs1987; 33 (2): 30–40.
13.
Van den HovenWE, HallDWR, BurnsJW: Inhibitory action of cyclandelate and a number of its metabolites on cyclic AMP phosphordiesterase. Br J Clin Pract1984; 34: 20–24.
14.
AndermannG, DietzM: Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas – liquid chromatography. J Chromatogr1981; 223: 365–370.
15.
AndermannG, DietzM: Dosage plasmatique et urinaire du 3,3,5-triméthylcyclohexanol libré et conjuguéJ Chromatogr1983; 272: 299–305.
